Chicago—May 8, 2026, 06:06 CDT.
Tempus AI locked in an upsized $400 million private sale of 0% convertible senior notes maturing in 2032, opting to swap out secured borrowings for debt with no periodic interest as it sharpens its focus on healthcare data and diagnostics. The deal, raised from the original $350 million, is slated for a May 12 close. Tempus plans to use the proceeds to pay off $307.7 million in loans, cover roughly $27.2 million for capped-call hedges, and for general corporate purposes.
Why it matters now: Just days after Tempus posted stronger first-quarter sales and bumped up its 2026 forecast, the company also revealed a deeper net loss. With that, the spotlight swings back to capital structure—not just revenue growth—as a central theme for the Tempus AI stock narrative.
U.S. markets hadn’t opened yet at the dateline. Tempus shares traded at $49.47, off $4.07 from where they settled last session, putting the company’s market cap around $8.85 billion.
Tempus AI’s first-quarter revenue hit $348.1 million, jumping 36.1% year over year. Diagnostics brought in $261.1 million, while Data and Applications — covering data licensing and modeling — added $87 million. The company boosted its 2026 revenue outlook to a range of $1.59 billion to $1.60 billion and now sees adjusted EBITDA around $65 million, excluding interest, taxes, depreciation and amortization.
Eric Lefkofsky, the founder and CEO, described the quarter as one of “strong financial and operational performance.” He singled out oncology diagnostics and data modeling as bright spots. Still, the company’s filing tells a messier story: net loss deepened to $125.9 million from $68.0 million in the same period last year, with total liabilities reaching $1.72 billion as of March 31. SEC
The notes come with a conversion feature, letting holders swap the debt for equity if certain criteria are met. The first conversion price hits roughly $69.26 per share—a 40% markup versus Tempus’s closing level on Nasdaq on May 7. Tempus also picked up a capped-call hedge, aiming to blunt dilution from a potential conversion, with that cap initially set at $98.94.
The move’s timing is likely to raise eyebrows, given that management struck a calm note on liquidity just days ago during the earnings call. Lefkofsky assured analysts that Tempus did not “need more cash” to run operations, and CFO James Rogers pointed to payables and bonuses as the reasons first-quarter free cash flow came in light. Rogers also projected “significant improvements” for the second quarter. The Motley Fool
Wall Street isn’t backing off. TD Cowen’s Dan Brennan stuck with his buy rating and nudged his Tempus target up to $68 from $65 as of May 6, according to MarketBeat data. Over at Investing.com, the firm pointed to solid genomics and data momentum, but flagged that Tempus barely topped estimates and continues to struggle with weak cash flow.
Tempus faces plenty of competition. In its filings, the company points to Roche’s Foundation Medicine and Guardant Health as key rivals on the precision oncology testing front, while it lists IQVIA and Flatiron Health in the data services arena. Some of these players come armed with bigger budgets, tighter relationships with payers, or outsized sales forces—advantages that count in a field where both adoption and reimbursement for tests often drag.
Partnerships are still front and center for the bull thesis. Tempus highlighted in its latest quarterly update a new strategic tie-up with Merck, plus an extension of its oncology-focused deal with Gilead around the Lens analytics platform. During the call, Lefkofsky noted that more major pharma players have started signing multi-year agreements to license Tempus’ de-identified data and use it to develop models.
The new debt doesn’t wipe out equity risk. Shares surging past the conversion price—and blowing through the hedge cap—would put dilution right back on the table. On the flip side, slower growth, mounting losses, or fresh reimbursement pressure and competition could all squeeze Tempus’s ability to actually turn sales into cash.
Tempus has picked up less expensive capital and given itself a wider berth to operate. Coming up: its first-ever investor day on May 29. Management plans to dig deeper into the Diagnostics and Data and Applications units then.
